<DOC>
	<DOCNO>NCT00961272</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics raltegravir cervicovaginal fluid compare blood plasma HIV-infected pre-menopausal woman .</brief_summary>
	<brief_title>Evaluating Pharmacokinetics 400 mg Oral Dose Raltegravir HIV-Infected Pre-Menopausal Women</brief_title>
	<detailed_description>Participants : Six HIV-positive pre-menopausal woman already undergo therapy raltegravir . Procedures ( method ) : This study conduct single site : University North Carolina Chapel Hill . An outpatient screening visit ass subject suitability willingness participate . During one pharmacokinetic visit woman ask self-collect cervicovaginal sample use cervicovaginal fluid aspirator follow time point : pre-dose 1 , 2 , 4 , 6 , 8 , 10 , 12 hour raltegravir 400mg dose administration . One 3mL EDTA tube collect time point analyze blood plasma . A follow-up safety visit complete within 30 day inpatient stay .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection document HIV serology detectable viral load Able provide inform consent In opinion investigator , able comply treatment regimen study procedure Currently receive raltegravir treatment HIV infection . Subjects must raltegravir least 3 week prior inpatient pharmacokinetic sampling stay . All woman reproductive potential ( reach menopause undergone bilateral oophorectomy , tubal ligation ) must negative serum Î²HCG pregnancy test perform screen . Subjects must test negative sexually transmit infection ( gonorrhea , chlamydia , trichomonas , bacterial vaginosis , syphilis ) screen All study volunteer must agree participate conception process ( e.g. , active attempt become pregnant ) . Subjects must willing abstain intercourse , vaginal instrumentation , include douching , within 48 hour prior study visit . If participate sexual activity could lead pregnancy study visit , female study volunteer/male partner must use least one reliable method contraception ( e.g. , condom , without spermicidal agent ; diaphragm cervical cap spermicide ; IUD ) Pregnancy Breastfeeding Any condition opinion investigator likely interfere followup ability take study medication appropriately A positive test bacterial vaginosis , syphilis , gonorrhea , chlamydia , trichomonas</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Pre-menopausal</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Women</keyword>
	<keyword>HIV-infected</keyword>
</DOC>